Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial.

Objective: To study the tolerability and efficacy of acipimox on hyperlipidemia and diabetes compensation in patients with NIDDM under conditions of a routine clinical practice.

Research Design And Methods: We recruited 121 patients (60 men and 61 women) from 10 participating clinical centers. They were randomly divided into two groups and treated for 3 mo either with acipimox (250 mg three times a day) or placebo, using an open study design.

[Personal experience with the hypolipidemic agent Olbetam-Acipimox in hyperlipoproteinemia associated with type II diabetes].

The objective of this work was to test in type II diabetics with hyperlipoproteinaemia the action of a new analogue of nicotinic acid--Acipimox (Olbetam, Farmitalia Carlo Erba). The investigation comprised 24 patients of whom 16 took for three months Olbetam (250 mg 3 x per day by the oral route) and 8 patients were given placebo. The investigated biochemical parameters were examined before administration of the preparation was started and 4 and 12 weeks following its administration.